Entheon Biomedical Corp.

Equities

ENBI

CA29383X2023

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 11:30:00 2024-04-26 am EDT			5-day change	1st Jan Change
0.16 ^CAD	+3.23%		0.00%	+60.00%

Apr. 18	Entheon Biomedical Corp. announced that it has received CAD 0.1475 million in funding	CI
Apr. 11	Entheon Biomedical Corp. announced that it expects to receive CAD 0.1475 million in funding	CI

Entheon Biomedical Corp. Announces Termination of Andrew Hegle as Chief Science Officer

August 31, 2023 at 07:07 pm EDT

Entheon Biomedical Corp. announced that the company has terminated Andrew Hegle's position as Chief Science Officer, effective July 31, 2023. Mr. Hegle will continue on the Company's Board of Directors.

Latest news about Entheon Biomedical Corp.

Entheon Biomedical Corp. announced that it has received CAD 0.1475 million in funding	Apr. 17	CI
Entheon Biomedical Corp. announced that it expects to receive CAD 0.1475 million in funding	Apr. 10	CI
Entheon Biomedical Corp. Reports Earnings Results for the Full Year Ended November 30, 2023	Mar. 25	CI
Entheon Biomedical Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2023	23-10-25	CI
Entheon Biomedical Corp. Announces Termination of Andrew Hegle as Chief Science Officer	23-07-31	CI
Entheon Biomedical Corp. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2023	23-07-26	CI
Heading Health Inc. announced that it has received $4.5 million in funding from a group of investors	23-06-28	CI
Entheon Biomedical Corp. Reports Earnings Results for the First Quarter Ended February 28, 2023	23-04-28	CI
Entheon Biomedical Corp. Announces Termination of Consulting Agreement with Cybin	23-04-28	CI
Entheon Biomedical Corp. Auditor Raises 'Going Concern' Doubt	23-03-22	CI
Entheon Biomedical Corp. Announces Resignation of Ruth Chun as Director	23-03-02	CI
Entheon Biomedical Corp. Announces CFO Changes	23-01-05	CI
Entheon Biomedical Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2022	22-10-31	CI
Entheon Biomedical Corp. Closes Patient Enrolment in its Clinical Research Study EBIQ-101	22-10-05	CI
Entheon Biomedical Corp. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2022	22-07-26	CI
Entheon Biomedical Corp. cancelled the transaction announced on April 5, 2022	22-06-06	CI
Entheon Biomedical Corp. Reports Earnings Results for the First Quarter Ended February 28, 2022	22-04-29	CI
Entheon Biomedical Corp. announced that it expects to receive CAD 3 million in funding	22-04-04	CI
Entheon Biomedical Corp. Reports Earnings Results for the Full Year Ended November 30, 2021	22-03-30	CI
Entheon Biomedical Corp. Auditor Raises 'Going Concern' Doubt	22-03-29	CI
Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel, New Clinical Research Platform	22-03-29	MT
Entheon Biomedical Corp. Announces Enrollment in Phase 1 Study of DMT	22-03-15	CI
Entheon Biomedical Corp. Announces EBIQ-101 First-Patient Dose	22-02-24	CI
Entheon Biomedical Partners with Wavepaths on Upcoming Observational Study	22-02-16	CI
Entheon Biomedical Corp. Announces the Approval of DMT Clinical Trial	22-02-03	CI

Chart Entheon Biomedical Corp.

Duration

Period

More charts

Company Profile

Entheon Biomedical Corp. is a Canada-based biotechnology research and development company. The Company is focused on treating addiction and substance-use disorders.

Sector

Biotechnology & Medical Research

Calendar

2024-07-22 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ENTHEON BIOMEDICAL CORP.	+60.00%	1.04M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research